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ABSTRACT
Objective. To investigate the clinical and 
laboratory patterns of HCV-unrelated CV, 
and the factors influencing its outcome. 
Methods. Prospective study of all anti-
HCV and HCV-RNA negative patients 
with CV have been observed since Jan-
uary 2004 in 17 centres participating 
in the Italian Group for the Study of 
Cryoglobulinaemias (GISC).  
Results. 175 enrolled were followed up 
for 677 person-years. The associated 
conditions were primary Sjögren’s syn-
drome (21.1%), SLE (10.9%), other auto-
immune disorders (10.9%), lymphopro-
liferative diseases (6.8%), solid tumours 
(2.3%) and HBsAg positivity (8.6%), 
whereas 69 patients (39.4%) had essen-
tial CV. There were significant differenc-
es in age (p<0.001), gender (p=0.002), 
the presence of purpura (p=0.005), ar-
thralgia (p=0.009), liver abnormalities 
(p<0.001), sicca syndrome (p<0.001), 
lymphadenopathy (p=0.003), spleno-
megaly (p=0.002), and rheumatoid fac-
tor titres (p<0.001) among these groups. 
Type II mixed cryoglobulins were present 
in 96 cases (54.9%) and were indepen-
dently associated with purpura and fa-
tigue (odds ratio [OR]4.3; 95% confi-
dence interval [CI] 1.8–10.2; p=0.001; 
and OR2.8; 95%CI 1.3–6.3; p=0.012). 
Thirty-one patients died during follow-
up, a mortality rate of 46/1000 person-
years. Older age (for each additional 
year, adjusted hazard ratio [aHR] 1.13; 
95%CI 1.06–1.20; p<0.001), male 
gender (aHR 3.45; 95%CI 1.27–9.40; 
p=0.015), type II MCG (aHR 3.31; 
95%CI 0.09–1.38; p=0.047) and HBsAg 
positivity (aHR 7.84; 95%CI 1.20–36.04; 
p=0.008) were independently associated 
with greater mortality. 
Conclusion. HCV-unrelated CV is a 
multifaceted and often disabling dis-
order. The associated conditions influ-
ence its clinical severity, giving rise 
to significantly different clinical and 
laboratory profiles and outcomes. 
Introduction
Mixed cryoglobulins (MCGs) are im-
mune complexes formed by antibodies 
mainly belonging to the IgG class, and 
a rheumatoid factor (RF)-like antibody, 
almost always an IgM (1, 2). Accord-
ing to Brouet et al. (3), type II MCG 
includes monoclonal IgMs, and type 
III polyclonal IgMs. Circulating MCGs 
can be detected in association with acute 
and chronic infections, lymphoprolif-
erative disorders and autoimmune dis-
eases (4-6), and are also a relatively fre-
quent finding in elderly people without 
any significant associated disorder (7). 
MCGs can cause the serious disease (4, 
8, 9) cryoglobulinaemic vasculitis (CV) 
and, in most cases, are associated with 
chronic HCV infection (10-15). HCV-
unrelated CV is relatively uncommon 
(16-18), accounting for 9–15% of all 
CV cases (17, 19). Autoimmune diseas-
es are a major source of non-infectious 
CV (20-24). An association with B-cell 
lymphomas has been clearly shown (4) 
(and also confirmed in HCV-negative 
cases) (17), and cryoglobulins can also 
be detected in some patients with solid 
cancers (25). Hepatitis B virus (HBV) 
is probably the cause of some cases of 
CV (26, 27), and a recent study has at-
tributed some sporadic cases to other vi-
ral, bacterial and parasitic diseases (27). 
Significant MCG levels have also been 
found as late as six months after the on-
set of the symptoms of acute Chikungu-
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nya virus infection (28). However, the 
real significance of cryoglobulinaemias 
in the course of infections other than 
HCV infection, and their propensity 
to evolve into full-blown chronic CV 
syndromes, are still debated. Essential 
CV is defined as the cases not associ-
ated with any known causative disease 
capable of inducing cryoglobulin pro-
duction (5).
Many aspects of the natural history 
and outcomes of HCV-unrelated CV 
have not yet been investigated, and all 
of the available come from retrospec-
tive studies and case reports. The aim 
of this study was to recruit and longi-
tudinally follow up patients presenting 
HCV-unrelated CV, and this report de-
scribes the clinical and laboratory char-
acteristics of CV in patients with each 
of the associated conditions, and the 
causes and predictive factors of death 
in the study cohort.
Methods
The participating centres enrolled all 
the patients with HCV-negative MCG 
who were being followed on 1 Janu-
ary 2004 (prevalent cases) or were 
diagnosed thereafter (incident cases). 
The patients’ anonymous data were 
collected at the time of enrolment and 
every 12 months during the follow-up 
period. The clinical manifestations to 
be reported included purpura, fatigue 
(defined as weakness even at rest and 
worsened by light exertion), arthral-
gia (lasting for at least three months 
or present in the form of two or more 
episodes per year), peripheral neuropa-
thy (confirmed by electrophysiological 
tests), Raynaud’s phenomenon, lower 
limb ulcers, chronic urticaria or other 
cutaneous manifestations, renal abnor-
malities (defined as proteinuria and/
or serum creatinine levels ≥1.5mg/
dL, with or without histological evi-
dence of glomerulonephritis), liver 
abnormalities (defined as at least three 
consecutive determinations of ab-
normal ALT levels and/or ultrasound 
evidence of fibrosis or steatosis of the 
liver or ultrasonographically confirmed 
hepatomegaly), ultrasonographically 
confirmed splenomegaly, lymphad-
enopathy involving one or more lymph 
node groups for at least three months, 
hyper-viscosity syndrome (evidence 
of one or more of headache, confu-
sion, blurred vision, visual and hearing 
loss, and epistaxis with instrumental 
evidence of increased blood viscosity), 
sicca syndrome (dry eyes and mouth 
for at least three consecutive months), 
hypertension (diastolic blood pressure 
>90 mmHg for at least six months), and 
lung abnormalities (asthma or chronic 
obstructive pulmonary disease [COPD] 
or pulmonary emphysema).
The laboratory tests requested upon 
enrolment and once a year during the 
follow-up were the determination of 
C3, C4 and rheumatoid factor (RF), 
serum protein electrophoresis, serum 
creatinine, AST, ALT, proteinuria, 
HbsAg, anti-HCV and HCV RNA. 
The cryoglobulin determinations and 
measurements were made in accord-
ance with the GISC protocol (29). The 
cryoglobulins were immunochemically 
characterised by means of immuno-
electrophoresis (29, 30). 
The inclusion criteria were cryoglobu-
lin positivity (cryocrit ≥0.5%); at least 
one episode of palpable purpura, or, al-
ternatively, arthralgia and fatigue with 
at least one of peripheral neuropathy, 
Raynaud’s phenomenon, lower limb 
ulcers or nephropathy, and C4 ≤8 mg/
dL during the year before enrolment; 
and negativity for HCV antibodies and 
HCV RNA at the time of enrolment. 
The exclusion criteria were type I 
cryoglobulinaemia, patients who had 
cleared HCV RNA after antiviral ther-
apy but maintained circulating cryo-
globulins, and those transient cryo-
globulinaemias associated with acute 
infections.
CV-associated autoimmune diseases 
were defined on the basis of the interna-
tional criteria (31-35), and grouped as 
CV associated with primary Sjögren’s 
syndrome (PSS), systemic lupus ery-
thematosus (SLE) or other autoimmune 
diseases (AID); the patients with non-
Hodgkin lymphoma (NHL), other lym-
phoproliferative disorders or monoclo-
nal gammopathy of uncertain signifi-
cance (MGUS) were grouped as having 
lymphoproliferative diseases (LPD); 
the patients who presented solid tu-
mours six months before or at the time 
of the first evidence of CV were includ-
ed in a separate group (ST), as were 
those who were HBsAg positive at the 
time of enrolment (HBCV). The cases 
of CV that were not associated with any 
diseases known to be a cause of cryo-
globulin production were defined as es-
sential cryoglobulinaemias (ECV).
The data were censored as of 31 August 
2015, and the patients were considered 
to be in follow-up until the date of the 
last available examination or the date 
of death. The predictability of different 
outcomes was compared in relation to 
the associated disorder and the type of 
MCG found at enrolment. Given the 
broad spectrum of disorders associated 
with cryoglobulinaemia and the variety 
of the treatments administered, the pre-
scribed therapies were not included in 
the present analyses.
The Mann-Whitney or Kruskal-Wallis 
non-parametric test and Pearson’s chi-
squared test (or Fisher’s exact test, 
when necessary) were respectively 
used to compare the continuous and 
categorical baseline variables of the 
patients in the groups of interest. In 
the longitudinal study, C4 values were 
compared using Wilcoxon’s test for 
paired samples. The risk factors cor-
related with the type of cryoglobuli-
naemia and the variables that indepen-
dently correlated with the risk of being 
no longer positive for MCG after 12 
months were analysed using logistic 
regression multivariate models. The 
survival analyses were made using the 
Kaplan-Meier method. The long-rank 
test was used to compare the survival 
curves between groups. The baseline 
clinical predictors of survival were as-
sessed using a multivariable Cox pro-
portional hazard regression model. All 
of the analyses were made using SAS 
9.3 (SAS Institute, Cary, NC).
Results
Between 1 January 2004 and 30 June 
2013, a total of 246 cases were reported 
by the 17 participating centre, but 71 
were excluded because the did not meet 
the inclusion criteria or the data were 
incomplete. The analysis were there-
fore based on 175 patients (37 males 
and 138 females), the last of whom was 
enrolled on 20 May 2013: 101 preva-
lent cases as of 1 January 2004 (18 
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males and 83 females) and 74 incident 
cases (19 males and 55 females). The 
associated diseases were PSS in 37 cas-
es (21.1%), SLE in 19 (10.9%), AID in 
19 (10.9%, including five patients with 
rheumatoid arthritis, four with mixed 
connective tissue disease, four with 
systemic sclerosis, and six with other 
AIDs), lymphoproliferative diseases in 
12 cases (6.8%, including six patients 
with NHL, two with Waldenström’s 
disease, and four with MGUS), solid tu-
mours in four patients (2.3%, including 
two follicular thyroid carcinomas, one 
lung cancer and one liver cancer). HB-
sAg was positive in 15 patients (8.6%) 
without any concomitant disease as-
sociated with cryoglobulin production. 
No underlying disease was found in 
69 patients (39.4%)  who were conse-
quently classified as having ECV.  
Women were more prevalent in all of 
the groups, but their frequency was 
significantly different, with the high-
est percentage having autoimmune dis-
ease-related CV (PSS, SLE and AID). 
In particular, 100% of the SLE cases 
were women, who were also signifi-
cantly younger than the others (Table I).
The prevalence of purpura in the cohort 
as a whole was 69.1%, with statisti-
cally significant differences among the 
groups. The lowest prevalence was in 
the patients with SLE, who also showed 
a significant correlation between purpu-
ra and sicca syndrome (p=0.048). There 
were significant between-group differ-
ences in the distribution of arthralgia, 
with the highest prevalence in the SLE 
group, which showed the lowest preva-
lence of the Meltzer and Franklin triad. 
There were also significant differences 
in the distribution of liver abnormali-
ties (more frequent in the patients with 
HBCV), sicca syndrome (more frequent 
in the patients with PSS), lymphad-
enopathy (less prevalent in the patients 
with ECV and AID), and splenomegaly 
(less frequent in the patients with PSS, 
SLE and ECV). 
The median C4 level in cohort as a 
whole was 4 mg/dL, (IQR 2-12) with-
out any significant between-group dif-
ferences, whereas the median RF titres 
were significantly different, being low-
est in the SLE and AID groups. The 
median cryocrit value was 2% (IQR 
0.50–4%) with non-significant varia-
tions among the groups.
Type II cryoglobulins were found in 
96 cases (54.9%), without any signifi-
cant between-group differences. The 
patients with type II MCG more fre-
quently had the Meltzer and Franklin 
triad, purpura, asthenia, ulcers and pe-
ripheral neuropathy, lower C4 levels, 
Table I. Baseline demographic, clinical and laboratory data relating to patients with HCV-unrelated CV (by associated disorder) or essential CV.
Baseline characteristics Total PSS SLE AID LPD ST HBCV ECV 
 n=175 n=37 n=19 n=19 n=12 n=4 n=15 n=69 p*
Females [n (%)] 138 (78.9) 35 (94.6) 19 (100.0) 17 (89.5) 8 (66.7) 3 (75.0) 10 (66.7) 46 (66.7) 0.002
Age (years) [median (IQR)] 66 (55-74) 67 (61-73) 46 (37-62) 60 (46-69) 77 (67-78) 75 (70-78) 63 (55-69) 68 (56-74) <0.001
Incident cases [n (%)] § 74 (42.3) 16 (43.2) 3 (15.8) 6 (31.6) 3 (25.0) 4 (100.0) 4 (26.7) 38 (55.1) 0.004
Purpura [n (%)] 121 (69.1) 29 (78.4) 7 (36.8) 12 (63.2) 10 (83.3) 4 (100.0) 14 (93.3) 45 (65.2) 0.005
Arthralgia [n (%)] 140 (80.0) 30 (81.1) 19 (100.0) 17 (89.5) 7 (58.3) 4 (100.0) 8 (53.3) 55 (79.7) 0.009
Fatigue [n (%)] 123 (70.3) 25 (67.6) 12 (63.2) 15 (78.9) 8 (66.7) 3 (75.0) 10 (66.7) 50 (72.5) 0.949
MF triad [n (%)] 68 (38.9) 15 (40.5) 4 (21.1) 8 (42.1) 4 (33.3) 3 (75.0) 7 (46.7) 27 (39.1) 0.493
Lower limb ulcers [n (%)] 31 (17.7) 8 (21.6) 3 (15.8) 4 (21.1) 4 (33.3) 2 (50.0) 1 (6.7) 9 (13.0) 0.234
Peripheral neuropathy [n (%)] 85 (48.6) 22 (59.5) 7 (36.8) 7 (36.8) 6 (50.0) 3 (75.0) 6 (40.0) 34 (49.3) 0.490
Renal abnormalities [n (%)] 46 (26.3) 13 (35.1) 8 (42.1) 6 (31.6) 3 (25.0) 2 (50.0) 4 (26.7) 10 (14.5) 0.075
Hyperviscosity syndrome [n (%)] 4 (2.3) 1 (2.7) 1 (5.3) 1 (5.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.5) 0.999
Raynaud’s phenomenon [n (%)] 46 (26.3) 10 (27.0) 9 (47.4) 6 (31.6) 3 (25.0) 0 (0.0) 0 (0.0) 18 (26.1) 0.060
Chronic urticaria or other 30 (17.1) 7 (18.9) 7 (36.8) 3 (15.8) 1 (8.3) 0 (0.0) 1 (6.7) 11 (15.9) 0.360 
   cutaneous manifestations¶ [n (%)] 
Liver abnormalities [n (%)] 41 (23.4) 4 (10.8) 2 (10.5) 2 (10.5) 3 (25.0) 1 (25.0) 12 (80.0) 17 (24.6) <0.001
Lung abnormalities [n (%)] 26 (14.9) 7 (18.9) 2 (10.5) 4 (21.1) 0 (0.0) 1 (25.0) 3 (20.0) 9 (13.0) 0.552
Sicca syndrome [n (%)] 68 (38.9) 32 (86.5) 8 (42.1) 10 (52.6) 3 (25.0) 0 (0.0) 3 (20.0) 12 (17.4) <0.001
Hypertension [n (%)] 66 (37.7) 17 (45.9) 3 (15.8) 8 (42.1) 7 (58.3) 2 (50.0) 7 (46.7) 22 (31.9) 0.171
Lymphadenopathy [n (%)] 34 (19.4) 13 (35.1) 6 (31.6) 2 (10.5) 3 (25.0) 2 (50.0) 3 (20.0) 5 (7.2) 0.003
Splenomegaly [n (%)] 27 (15.4) 3 (8.1) 1 (5.3) 3 (15.8) 5 (41.7) 2 (50.0) 6 (40.0) 7 (10.1) 0.002
C4 (mg/dL) [median (IQR)] 4 (2-12) 4 (2-11) 4 (3-10) 8 (1-14) 2 (1-5) 7 (4-12) 2 (1-8) 5 (2-15) 0.544
RF (kU/L) [median (IQR)] 109 (20-372) 239 (90-504) 15 (9-19) 20 (5-58) 341 (106-589) 603 (309-1433) 220 (111-2935) 101 (22-238) 0.001
Cryocrit (%) [median (IQR)] 2.0 (0.5-4.0) 2.0 (0.9-7.0) 1.0 (1.0-2.0) 0.5 (0.5-3.1) 5.5 (3.3-6.5) 6.0 (1.6-12.0) 2.0 (2.0-17.0) 1.2 (0.5-3.0) 0.061
Type of MCG [n (%)]                 0.134
      Type II 96 (54.9) 24 (64.9) 6 (31.6) 8 (42.1) 9 (75.0) 2 (50.0) 10 (66.7) 37 (53.6)  
      Type III 79 (45.1) 13 (35.1) 13 (68.4) 11 (57.9) 3 (25.0) 2 (50.0) 5 (33.3) 32 (46.4) 
*p-values are for χ2 or Fisher’s exact test and Kruskal-Wallis test when comparing all groups in  the analysis of each category. ¶ Other than palpable purpura 
and ulcers.
§ Diagnosed after 1 January 2004.
PSS: primary Sjögren’s syndrome; SLE: systemic lupus erythematosus; AID: other auto-immune disorders; LPD: lymphoproliferative diseases. ST: solid tu-
mours; HBCV: HBsAg positive cryoglobulinaemic vasculitis; ECV: essential cryoglobulinaemic vasculitis.
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and higher cryocrit concentrations than 
those with type III MCG (Table II). 
On the contrary, arthralgia was more 
frequent in the patients with type III 
MCG. Purpura (odds ratio [OR] 4.3; 
95% confidence Interval [CI] 1.8–10.2; 
p=0.001) and fatigue (OR 2.8; 95%CI 
1.3–6.3; p=0.012) were independently 
associated with type II MCG, whereas 
arthralgia was negatively related (OR 
0.3; 95% CI 0.1–0.8; p=0.016).
Twelve months after enrolment, 23.4% 
of the patients (36/154) were MCG 
negative. The predictors of becoming 
MCG negative during follow-up were 
a longer time since the first diagnosis 
of CV, and the presence of cutaneous 
manifestations, liver abnormalities, 
lymphadenopathy and type III cryoglo-
bulins at enrolment (Table III). 
In the patients who became MCG nega-
tive, the median C4 level significantly 
increased from 4mg/dL (IQR 1–9) at 
baseline to 9 mg/dL (IQR 3–17) at the 
time of the negative cryoglobulin test 
(p<0.001). Becoming MCG negative 
during follow-up independently corre-
lated with the time since the diagnosis 
of CV (OR 1.1 for each additional year; 
95%CI 1.0–1.2; p=0.002) and the ab-
sence of fatigue at the time of enrolment 
(OR 0.3; 95%CI 0.1–0.9; p=0.033). 
MCG became negative during the first 
year of follow-up in 43.8% of the pa-
tients with SLE and in 38.5% of those 
of HBCV, but in only 13.7% of those 
with ECV and 16.7% of those with 
AID; in the other three groups, about 
25% of the patients became MCG nega-
tive. The percentage of patients who be-
came MCG negative was significantly 
lower in the ECV group than in the 
other groups taken together (13.7% vs. 
29.1%, p=0.029). Fifty-seven (35.2%) 
of the 162 patients for whom this in-
formation was available became MCG 
negative at some time during the follow-
up. The time from the first diagnosis of 
CV was longer in these patients than 
in those who remained MCG positive 
(p<0.001), they were more frequently 
women (p=0.005), and they more fre-
quently had Raynaud’s phenomenon 
(p=0.008), cutaneous manifestations 
other than lower limb ulcers (p=0.025), 
liver abnormalities (p=0.029), and lym-
phadenopathy (p=0.001).
The patients were followed-up for a to-
tal of 677 person-years (p-y). The medi-
an follow-up time was 37 months (IQR 
12–67), and was significantly different 
between the groups, being significantly 
shorter in the LPD group. Seven pa-
tients died and four were lost to follow-
up within 12 months of enrolment.
A total of 31 patients (10 males and 21 
females) died during the follow-up, a 
mortality rate of 4.6 per 100 p-y. The 
median age at death was 75 years (IQR 
67–83). The causes of deaths are de-
scribed in Table IV. 
Figure 1 (panel A) shows the time-
dependent survival probability in the 
cohort as a whole. The Kaplan-Meier 
survival estimates (95% CI) were 
0.92 (0.87–0.96) at the end of the first 
year of follow-up, 0.82 (0.74–0.89) at 
the end of the fourth year, and 0.66 
(0.54–0.79) at the end of the eighth 
year. The probability of survival was 
significantly lower among the males 
(Fig. 1, panel b, p=0.004) and lower 
(of borderline statistical significance) 
among the patients with type II MCG 
at baseline (Fig. 1 panel c, p=0.072). 
The patients with purpura had a lower 
survival probability than those without 
(Fig. 1 panel d, p=0.043). 
Mortality was lower in the SLE and 
AID groups taken together than in the 
other groups (Fig. 2, p=0.004), and 
higher during the first two years of fol-
low-up in the HBCV group. 
Univariate analysis showed that male 
gender and each additional year of 
age were correlates of a higher risk of 
death, whereas each additional year 
from CV diagnosis and having SLE/
AID were protective factors (Table V).
Multivariate analysis confirmed that 
an older age and male gender were 
independently associated with greater 
mortality, and showed that having type 
II MCG and belonging to the HBCV 
group were also independent correlates 
of greater mortality.
Discussion
The findings of this study confirm that 
HCV-unrelated CV is not a benign dis-
ease. One of the aims of the study was 
Table II. Baseline characteristics of 175 patients with HCV-unrelated CV by type of MCG.
Characteristics  Type II Type III  
 n = 96 n = 79 p*
Female [n (%)] 72 (75.0) 66 (83.5) 0.168
Age (years) [median (IQR)] 66 (57-74) 64 (47-74) 0.419
Incident cases [n (%)] § 38 (39.6) 36 (45.6) 0.425
Purpura [n (%)] 82 (85.4) 39 (49.4) <0.001
Arthralgia [n (%)] 69 (71.9) 71 (89.9) 0.003
Fatigue [n (%)] 75 (78.1) 48 (60.8) 0.012
MF triad [n (%)] 46 (47.9) 22 (27.8) 0.007
Lower limb ulcers [n (%)] 23 (24.0) 8 (10.1) 0.017
Peripheral neuropathy [n (%)] 55 (57.3) 30 (38.0) 0.011
Renal abnormalities [n (%)] 26 (27.1) 20 (25.3) 0.792
Hyperviscosity syndrome [n (%)] 3 (3.1) 1 (1.3) 0.628
Raynaud’s phenomenon [n (%)] 25 (26.0) 21 (26.6) 0.936
Chronic urticaria or other cutaneous 12 (12.5) 18 (22.8) 0.072 
   manifestations¶  [n (%)] 
Liver abnormalities [n (%)] 26 (27.1) 15 (19.0) 0.208
Lung abnormalities [n (%)] 13 (13.5) 13 (16.5) 0.590
Sicca syndrome [n (%)] 38 (39.6) 30 (38.0) 0.828
Hypertension [n (%)] 37 (38.5) 29 (36.7) 0.803
Lymphadenopathy [n (%)] 17 (17.7) 17 (21.5) 0.526
Splenomegaly [n (%)] 19 (19.8) 8 (10.1) 0.078
C4 (mg/dL) [median (IQR)] 3 (1-8) 7 (3-14) 0.009
RF (kU/L) [median (IQR)] 135 (30-495) 49 (19-278) 0.141
Cryocrit (%) [median (IQR)] 3.0 (1.0-9.0) 1.0 (0.5-2.0) 0.001
*p-values are for χ2 or Fisher’s exact test and Mann-Whitney test. § Diagnosed after 1 January 2004. 
¶ Other than palpable purpura and ulcers.    
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to identify the disorders that are more 
likely to be responsible for chronic CV 
and differentiate them from transient 
cryoglobulinaemia of no pathological 
significance. The overlapping of some 
of the signs and symptoms of CV with 
those characterising the associated dis-
eases may be a major confounding fac-
tor. After carefully examining the clini-
cal and laboratory data, about 30% of 
the cases proposed for enrolment in the 
study were excluded, mainly because 
they presented MCG accompanied by 
symptoms compatible with the under-
lying disease but not sufficient for a di-
agnosis of CV on the basis of our inclu-
sion criteria. When the study was de-
signed in 2003, there were no validated 
CV classification criteria, but those 
recently proposed by the GISC (36, 37) 
perform well also in the case of HCV-
unrelated CV (38) (albeit with slightly 
lower specificity), and are currently un-
der evaluation in this case series. 
As in the case of HCV-associated cryo-
globulinaemias (15, 16, 39), CV is 
significantly more frequent in females 
aged >60 years. This finding is similar 
to that described by Foessel et al. (18) 
in their study of type II MCGs, and that 
found in a larger French study (20).
Palpable purpura was  observed in 75% 
of the cases of Terrier et al. (40) and 
in 69.1% of our patients, and in 78% 
and 85.4% of the patients with type II 
MCG. In our series, it was also one of 
the factors independently associated 
with type II MCG, although it does 
not seem to be a predictor of MCG 
persistence as its prevalence was simi-
lar in the patients who became MCG-
negative during follow-up and in those 
who continued to produce them. On the 
other hand, the loss of MCG produc-
tion was predicted by the time from the 
first MCG-positive test, thus suggest-
ing that longer treatment exposure may 
influence their clearance. 
Peripheral neuropathy (PN) is fre-
quently part of CV syndrome, and 
sometimes the first sign of cryoglobuli-
naemia (5, 41, 42). In an Italian study, 
52% of the patients with HCV related 
CV had PN (39), which is similar to the 
approximately 49% prevalence in our 
study. Taken together, these findings 
confirm that PN is frequent in patients 
with CV regardless of its cause. More-
over, it was significantly more frequent 
in patients with type II MCG. 
Lung disorders were frequently seen in 
our case series, mainly in elderly pa-
tients and without a clear-cut relation-
ship with CV. Fewer than 3% of the pa-
tients were affected by hyperviscosity 
syndrome (about the same percentage 
as that reported among HCV-related 
cases) (15, 43), thus confirming that it 
is uncommon in mixed cryoglobulinae-
mias regardless of their cause. 
Sicca syndrome is frequently observed 
in patients with HCV infection (44, 45), 
and in those with HCV-associated CVs 
(46). In our series, it was not only fre-
quent in patients with autoimmune dis-
orders, but also relatively frequent in 
those with HBCV and ECV. The recent 
demonstration of salivary gland epi-
thelial cell infection by human T-lym-
phtropic virus-1 (HTLV-1) (47), and 
previous data concerning the presence 
of HTLV-1 infection in patients with 
ECV (48) suggest that the role of this 
Table III. Baseline characteristics of patients who did or did not continue producing mixed 
cryoglobulins (MCG) 12 months after enrolment.
                            
 MCG
 
Characteristics Permanently Negativised p*
 positive n=36 
 n=118  
 
Female [n (%)] 89 (75.4) 32 (88.9) 0.085
Age (years) [median (IQR)] 64 (55-74) 66 (55-75) 0.823
Years since diagnosis [median (IQR)] 5 (2-9) 13 (4-17) <0.001
Purpura [n (%)] 80 (67.8) 24 (66.7) 0.899
Arthralgia [n (%)] 95 (80.5) 30 (83.3) 0.704
Fatigue [n (%)] 90 (76.3) 22 (61.1) 0.074
MF triad [n (%)] 49 (41.5) 12 (33.3) 0.379
Lower limb ulcers [n (%)] 22 (18.6) 5 (13.9) 0.511
Peripheral neuropathy [n (%)] 55 (46.6) 16 (44.4) 0.820
Renal abnormalities [n (%)] 33 (28.0) 11 (30.6) 0.763
Hyperviscosity syndrome [n (%)] 4 (3.4) 0 (0.0) 0.574
Raynaud’s phenomenon [n (%)] 28 (23.7) 14 (38.9) 0.074
Chronic urticaria or other cutaneous 16 (13.6) 11 (30.6) 0.019 
   manifestations¶  [n (%)] 
Liver abnormalities [n (%)] 23 (19.5) 14 (38.9) 0.017
Lung abnormalities [n (%)] 14 (11.9) 4 (11.1) 0.902
Sicca syndrome [n (%)] 46 (39.0) 14 (38.9) 0.992
Hypertension [n (%)] 41 (34.7) 16 (44.4) 0.291
Lymphadenopathy [n (%)] 16 (13.6) 15 (41.7) <0.001
Splenomegaly [n (%)] 19 (16.1) 5 (13.9) 0.749
C4 (mg/dL) [median (IQR)] 5 (2-15) 4 (1-9) 0.091
RF (kU/L) [median (IQR)] 119 (21-386) 114 (22-546) 0.743
Cryocrit (%) [median (IQR)] 2.0 (0.5-5.0) 1.8 (0.9-4.5) 0.952
Type of MCG [n (%)]         0.015
      Type II 73 (61.9) 14 (38.9) 
      Type III 45 (38.1) 22 (61.1)  
Associated disorder [n (%)]     0.133
      PSS 24 (20.3) 9 (25.0)  
      SLE 9 (7.6) 7 (19.4) 
      AID 15 (12.7) 3 (8.3)  
      LPD 9 (7.6) 3 (8.3) 
      ST 3 (2.5) 1 (2.8)  
      HBCV 8 (6.8) 5 (13.9) 
      ECV 50 (42.4) 8 (22.2)  
p-values are for χ2 or Fisher’s exact test and Mann-Whitney test.
¶Other than palpable purpura and ulcers.    
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Table IV. Causes of death in 31 patients with HCV-unrelated CV.
Associated Observed deaths Percentage of total number Notes
  disorder   of observed deaths 
 No. %  
PSS 9/37 24.3 29.0 Four deaths were caused by NHL occurring after enrolment,  three cardiac-related deaths,  
   and  one due to renal insufficiency and rituximab-induced severe thrombocytopenia. The cause  
    of death was unknown in one case.
SLE 1/19 5.2 3.2 Caused by gastric bleeding
AID 1/19 5.2 3.2 Caused by suicide
LPD 0/12 - - Nine patients were lost to follow-up. The other three patients (with  Waldenström disease,   
    gastric MALT lymphoma and MGUS respectively) were still alive at the time of data 
    analysis.
ST 1/4 25.0 3.2 One patient with primary liver cancer died 28 months after diagnosis. This patient was 
    repeatedly HBsAg and HCV RNA negative, but positive for anti-HBc antibodies. Two 
    patients with follicular thyroid carcinomas were transferred to oncological centres and lost  
   to  follow-up. The last patient had a diagnosis of lung carcinoma in 2004 and was still alive in  
    2011, when she was lost to follow-up.
HBCV 6/15 40.0 19.4 The causes of death were different in each patient and included NHL, hepatitis B 
    exacerbation, acute pneumonia, renal insufficiency, cachexia in Wernike’s encephalopathy,  
    and cardiac arrest in senile marasmus.
ECV 13/69 18.8 42.0 There were three cardiac deaths, three cases of pneumonia (one after treatment with 
    rituximab), one NHL, one lung carcinoma, one death due to gastric bleeding, and one case  
    of stroke. The cause of death was unknown in three cases.
Fig. 1. Time-dependent cumulative probability of survival during follow-up: overall probability (panel A); males vs. females (panel B); type II vs. type III 
cryoglobulinaemia (panel C) ); patients with vs. patients without purpura (panel D).
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virus as a possible cause of EMC with 
sicca syndrome should be reassessed.
In comparison with HCV-related CV 
(39), the historical GISC series (9). and 
the French HCV-negative series (20), 
the median cryocrit levels observed 
in our cohort at the time of enrolment 
was relatively low. However, almost all 
of the patients included in 2004 were 
on treatment with immunosuppressive 
drugs or steroids and, in the majority of 
cases, their cryocrit levels at enrolment 
were considerably lower than those 
previously observed. 
It has been hypothesised that cryopre-
cipitating RF production proceeds from 
poly-clonality (i.e. type III cryoglobu-
lins) to oligo-clonality, and finally mo-
no-clonality (13, 49). In patients with 
HCV-related CV, the development of 
type II MCG is considered a hallmark 
of CV (13, 50, 51),  but whether or not 
the type III MCG produced in associa-
tion with certain diseases progress to-
wards monoclonality is still unknown. 
Type III MCGs were more frequent 
in our cases than in the French series 
(40), in which haematologic and con-
nective tissue diseases accounted for 
respectively 30% and 22% of the cases 
whereas, after excluding the HbsAg-
positive patient, LPD and connective 
tissue diseases accounted for 7.5% and 
46.9% of the cases in our series. It is 
conceivable that this case mix was due 
to the characteristics of the GISC cen-
tres, which are mainly rheumatology 
centres. 
The Kaplan-Meier survival estimates in 
our cohort were quite similar to those 
of Terrier et al., (40) and an older age 
and male gender were independently 
associated with a poor prognosis in 
both studies. This finding strongly sug-
gests that, although less frequent, CV 
may be a more serious disease in males 
than in females. Type II MCG, which is 
an independent risk factor of increased 
mortality, was further confirmed as a 
marker of advanced disease.
MCGs have been reported in 10–15% 
of patients with PSS (17, 52), which our 
study confirms to be a leading cause of 
HCV-unrelated CV. Overt purpura was 
present in 78% of our PSS patients, 
64% of whom had type II MCGs that 
persisted over time in more than 70% 
of cases. During the study period, four 
PSS patients died because of NHL. It 
is known that PSS increases the risk of 
developing B-cell NHL (23, 53, 54), 
and PSS patients show a polyclonal pat-
tern of B cell expansion in bone mar-
row more frequently than patients with 
HCV-related cryoglobulinaemia (46). 
The clinical and laboratory profile of 
SLE-related CV was significantly dif-
ferent from those of the other groups. 
The cessation of MCG production dur-
ing the first year after enrolment may 
be due to the fluctuating nature of auto-
antibody production in SLE, but also 
to SLE treatment. However, how many 
SLE patients with MCGs have real CV 
and the role of MCGs in the natural 
history of SLE are still unclear.
In the AID group, cryocrit and RF con-
centrations tended to be higher in the 
patients with RA or mixed connective 
tissue disease than in the others. All 
of the patients with systemic sclerosis 
had Raynaud’s phenomenon, sicca syn-
drome and type III MCGs, and lower 
limb ulcers were recorded in 3 cases, 
but purpura was recorded in only one 
patient who had the lowest median RF 
titre in the AID group. Taken together, 
these findings suggest that the inclu-
sion criteria adopted in this study may 
be unable to identify real CV in pa-
tients with autoimmune diseases. 
Waldenström’s disease is more fre-
quently described as a cause of type I 
cryoglobulinaemia, but the two cases 
found in our study confirm our previ-
ous observation about its possible in-
volvement in MCG (4, 9).
Fig. 2. Time-dependent cumulative probability of survival during follow-up by CV-associated disorder.
Table V. Variables associated with an increased risk of dying during follow-up (Cox model).
  Univariate analysis Multivariate analysis
  HR 95% CI p-value  HR 95% CI p-value
Age (for each additional year) 1.06 1.03-1.09 <0.001 1.13 1.06-1.20 <0.001
Male gender 2.97 1.37-6.45 0.006 3.45 1.27-9.40 0.015
Years since diagnosis  0.94 0.88-0.99 0.036 0.93 0.84-1.02 0.118
   (for each additional year) 
Purpura 2.82 0.98-8.07 0.05 0.35 0.09-1.38 0.134
Type II cryoglobulinaemia 2.00 0.92-4.35 0.079 3.31 1.02-10.78 0.047
ECV 1 - - 1 - -
SLE/AID 0.13 0.03-0.60 0.009 0,73 0.08-6.99 0.782
PSS 1.04 0.44-2.46 0.924 1,83 0.56-5.93 0.314
HBCV 1.60 0.60-4.26 0.349 7,84 1.70-36.04 0.008
MCG negative after 12 months 0.51 0.17-1.53 0.228  0.39 0.10-1.61 0.195
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The association of CV with solid tu-
mours seems to be uncommon, as has 
also been suggested by other studies 
(25). Purpura was present in all four of 
our cases, three of whom continued to 
produce MCGs during the follow-up, 
thus preventing us from excluding the 
possibility that CV may be a paraneo-
plastic syndrome in some cases. The 
positivity of anti-HBc antibodies in a 
patient with CV who died of primary 
liver cancer raises the question of the 
role of occult HBV infection in causing 
both disorders.
The reported percentage of CV caused 
by HBV ranges from 0.5% to 3% (16, 
17). HBsAg was positive in 5.8% of 
the 717 patients in the GISC series for 
whom this information was available.9 
After excluding the patients with evi-
dence of liver disease, its prevalence 
was similar to that of blood donors liv-
ing in the same area (55). These obser-
vations originally led us to conclude 
that HBV does not play a pivotal role 
in causing CV and that it may play an 
aetiological role in just a small minor-
ity of cases. Accordingly, Terrier et al. 
reported a total of only ten HBV-related 
cases (27), even if another study de-
scribed 48 patients (56) (ten of whom 
were part of a group of North African 
Jewish women with Raynaud’s syn-
drome) (57) and eight further cases 
were found in a retrospective survey 
carried out in China (58). However, the 
finding of only one HBV-related CV 
in the GISC population-based survey7 
further suggests that it is rare. No study 
has yet investigated what percentage 
of patients with chronic HBV infection 
may develop CV. It has been recently 
suggested that, like HCV, HBV may 
cause MGC by protracting the antigen-
ic stimulation of VH1-69-expressing 
B cells (59). Our study adds 15 un-
published cases to the relatively small 
number of known patients with HBV-
related CV, 12 of whom showed signifi-
cant liver abnormalities at the time of 
enrolment, thus suggesting active liver 
disease in most cases. Moreover, 14 of 
the 15 patients had purpura and 10 had 
type II MCG, and multivariate analysis 
showed that they were at increased risk 
of death. Given the small number of 
cases and the different timing of antivi-
ral treatment, it was not possible to state 
whether antiviral drugs influenced their 
outcomes or the disappearance of MCG 
during the follow-up. Interestingly, ex-
cluding these HBV-associated cases, 
none of the infection-related cases of 
MCG observed during the study period 
fulfilled our inclusion criteria.
True cases of ECV are probably rare as 
just one patient with overt CV unrelated 
to any other disease was found in the 
GISC population–based study (7). De-
spite this, ECV was the largest group in 
our study and in two other major series 
(16, 20), thus accounting for more than 
40% of the patients with HCV-unrelat-
ed CV. Type III MCG was more repre-
sented in our ECV patients (46%)  than 
in the French series (about 14%) (20). 
However, a number of our ECV cases 
evolved into type II MCG during the 
follow-up. The fact that these patients 
became MCG negative less frequently 
than the others may be due to the less 
effective treatment available for ECV. 
In conclusion, our findings confirm that 
CV is a multifaceted and often disa-
bling disorder also in HCV-negative 
cases. Male patients with purpura and 
type II MCG experience the worst out-
comes, regardless of the underlying 
disease. Each associated condition in-
fluences the clinical severity and stabil-
ity of MCG production differently over 
time, and leads to significantly differ-
ent clinical and laboratory profiles and 
outcomes. The most divergent groups, 
SLE and AID, were also those in which 
the inclusion criteria used in this study 
had major limitations due to the over-
lap of some of the symptoms frequently 
associated with these disorders (e.g. 
Raynaud’s phenomenon) and the symp-
toms of CV. Essential MCGs remain an 
enigma that the longer follow-up of this 
cohort might contribute to solve.
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